Jordi Fornaguera-Abril

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Journal: Molecular oncology

Published: May 29, 2025

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 25, 2025

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC.

Journal: JHEP reports : innovation in hepatology

Published: April 05, 2024

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.

Journal: Journal of hepatology

Published: February 02, 2024

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.

WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma.

Journal: Nature cancer

Published: September 21, 2022

Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.

Identification of IGF2 as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma.

Journal: Molecular cancer therapeutics

Published: May 11, 2022

Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.

Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 12, 2021

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: November 25, 2020

Metabolic Landscape of the Mouse Liver by Quantitative 31 P Nuclear Magnetic Resonance Analysis of the Phosphorome.

Metabolic Landscape of the Mouse Liver by Quantitative 31 P Nuclear Magnetic Resonance Analysis of the Phosphorome.

Journal: Hepatology (Baltimore, Md.)

Published: July 01, 2020

Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.

Liver Injury Increases the Incidence of HCC following AAV Gene Therapy in Mice.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: June 19, 2020

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.

Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications.

Journal: Journal of hepatology

Published: September 05, 2019

Showing 1-11 of 11

Last Updated: 09/26/2026